Jump to ContentJump to Main Navigation


Open Access
* Prices subject to change. Shipping costs will be added if applicable.

See all formats and pricing

Open Access
*Prices subject to change. Shipping costs will be added if applicable.

    Cancer Metabolomics

    1 Issue per year


    VERSITA Emerging Science

    Open Access

    cancer cells have fundamentally altered cellular metabolism which directly contributes to tumorigenicity and malignancy. Deciphering the full scope of dysregulated metabolism in cancer and its relevance to disease pathogenesis and potential therapeutic relevance requires the advancement of technologies to identify altered enzymes, metabolites, and metabolic pathways in cancer. This journal will specifically cover the development and use of metabolomic platforms to map altered metabolic pathways that drives cancer pathogenicity, or the discovery of metabolite biomarkers for cancer diagnosis. Not only will we cover aspects involving how metabolism influences cancer pathogenicity, but also the development of metabolomic technologies and associated bioinformatics for data analysis.

    Aims and Scope

    Why subscribe and read

    Cancer Metabolomics is dedicated to publishing the latest information on using and developing metabolomic technologies to investigate how cellular metabolism in cancer cells are altered to influence their pathogenic state. This journal will also be the primary hub for publishing advances in metabolomic technologies and data analysis, with an emphasis on cancer biology. This journal will also include discoveries of novel metabolite biomarkers for diagnosing cancer. Metabolomics, an essential discipline in system biology, plays the crucial role in basic sciences, translational sciences and application of personalized medicine in the area of oncology including prevention, early diagnosis and novel treatment. Presently, there are numerous translational and clinical laboratories working in the area of cancer metabolomics – but there is no scientific journal which would cover this topic. The “Cancer Metabolomics” is aimed to fill this existing gap. Topics include, but are not limited to:

    • Using metabolomic technologies to map dysregulated metabolism in cancer,
    • Using metabolomics technologies to annotate enzyme function in cancer,
    • Metabolomics technology development—mass spectrometry, NMR, MRI, PET,
    • Metabolomic imaging approaches,
    • High-throughput metabolomic analysis,
    • Analytical methods and bioinformatics for metabolomics data,
    • Discovery of metabolite biomarkers for cancer,
    • Elucidation of metabolic pathways/ fluxes using NMR and LC/MS,
    • Basic science and translational application of metabolomics in oncology,
    • Cross-validation of metabolomics protocols and data-sets in oncology,
    • Reports from the international meetings in the area of cancer metabolomics.

    The Open Access module allows ready access to its target audience and the peer-review system together with the outstanding scientists of the advisory board, editors and contributing authors ensures that quality and state-of-the-art technology and information is maintained throughout.

    Why submit

    Cancer Metabolomics is a new peer-reviewed journal which is aimed to cover a significant gap in technology development, utilization, and systems biology application in the area of oncology. The journal offers fast and comprehensive peer-review by outstanding scientists in the area of cancer metabolism, cancer biology, chemical biology, metabolomics, bioinformatics, mass spectrometry, and NMR.  The journal serves the needs of distinguished and young scientists focused on the development of basics, translational and clinical oncology research and consolidates the peer-reviewed metabolomics articles in the area of cancer metabolism using modern technological platform. The prominent members of the journals Advisory Board actively engage in the promotion of Cancer Metabolomics world-wide and establish opportunities to integrate with the latest results being disseminated at conferences, federal agencies and pharmaceutical companies as well as philanthropic organizations.

    Instructions for Authors


    Manuscripts should be submitted to the journal via email to the Journal Editor at canmet.editorial@degruyteropen.com.

    Authors are suggested to follow Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from the International Committee of Medical Journal Editors (ICMJE).

    Manuscript submitted to this journal should:

    • contain original work - not published elsewhere in any medium (in the whole or in part) by the authors or anyone else and not under consideration for publication in any other medium;
    • focus on the aims and scope of the journal;
    • be clearly and correctly written - should contain all essential features of a scientific publication that is easy to understand for the target audience;
    • written in English - attention to detail of the language will avoid severe misunderstandings which might lead to rejection of the paper;
    • be delivered in electronic format.

    The journal accepts the following publication formats:

    • Research Articles
    • Communications and Rapid Communications
    • Reviews and Mini-Reviews
    • Commentaries
    • Letters to the Editor and Amendments

    Cover Letter

    It is important that authors include a cover letter with their manuscript. Please explain why you consider your manuscript as suitable for publication in the journal, why will your paper inspire the other members of your field, and how will it drive research forward.
    The letter should contain all important details such as:

    • your full name (submitted by) 
    • full title of article and short title 
    • full list of authors with affiliations
    • e-mail of the corresponding author
    • contact address, telephone/fax numbers of the corresponding author
    • number of attached files, if there is more than one
    • status: new, reviewed or accepted (with reference ID if reviewed or accepted)

    Cover letter should explicitly state that the manuscript (or one with substantially the same content, by any of the authors) has not been previously published in any language anywhere and that it is not under simultaneous consideration or in press by another journal. If related work has been submitted, then we may require a preprint to be made available. Reviewers will be asked to comment on the overlap between the related submissions.

    Manuscripts that have been previously rejected, or withdrawn after being returned for modification, may be resubmitted if the major criticisms have been addressed. The cover letter must state that the manuscript is a resubmission, and the former manuscript number should be provided.

    Conflict of interest declaration
    To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest in connection with evaluated manuscripts (see Editorial Policy for details). Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Journal Editor.

    Open Access License
    Authors have to sign an Open Access License that is available on the journal webpage. We encourage the authors to send the signed license along with the manuscript. Please note, that no article will be published unless the Open Access License is signed.

    Formatting Requirements
    We accept submission of text, tables and figures as separate files or as a composite file. For your initial submission, we recommend you upload your entire manuscript, including tables and figures, as a single PDF file. If you are invited to submit a revised manuscript, please provide us with individual files: an editable text and publication-quality figures.

    • Text files can be submitted in the following formats: MS Word - standard DOCUMENT (.DOC) or RICH TEXT FORMAT (.RTF); PDF (not applicable for re-submitted or accepted manuscripts, see below)
    • Tables should be submitted as MS Word or PDF (not applicable for re-submitted or accepted manuscripts, see below). Please note that a straight Excel file is not an acceptable format
    • Graphics files can be submitted in any of the following graphic formats: EPS; BMP; JPG; TIFF; GIF or PDF. Please note that Powerpoint files are not accepted

    Post acceptance, text files of the revised manuscript and tables are required for use in the production.

    Authors should clearly indicate location of tables and figures in the text if these elements are given separately or at the end of the manuscript. If this information is not provided to the editorial office, we will assume that they should be left at the end of the text.

    For further instructions, please carefully follow the guidelines described in Instructions for Authors.

    Cancer Metabolomics is covered by the following services:

    • Celdes
    • CNPIEC
    • EBSCO Discovery Service
    • Google Scholar
    • J-Gate
    • Naviga (Softweco)
    • Primo Central (ExLibris)
    • PubsHub
    • Summon (Serials Solutions/ProQuest)
    • TDOne (TDNet)
    • Ulrich's Periodicals Directory/ulrichsweb
    • WorldCat (OCLC)

    Journal Editor
    Daniel K. Nomura, University of California, Berkeley, USA

    Editorial Advisory Board
    Leo L. Cheng, Harvard University, USA
    Kristine Glunde, The Johns Hopkins School of Medicine, USA
    Jason Locasale, Cornell University, USA
    Emmanuelle J. Meuillet, The University of Arizona, USA
    Alan Saghatelian, Harvard University, USA
    Natalie J. Serkova, University of Colorado, USA
    Kathleen A. Stringer, University of Michigan, USA
    Gary Suizdak, The Scripps Research Institute, USA
    Gary Patti, Washington University, USA
    Joshua Rabinowitz, Princeton University, USA
    Eranthie Weerapana, Boston College, USA

    Assistant Editors
    Daniel I. Benjamin, University of California, USA
    Melinda Mulvihill, University of California, USA
    Rebecca Kohnz, University of California, USA

    Language Editors
    Ramandeep Dhillon, University of California, USA
    Daniel Medina-Cleghorn, University of California, USA

    Editorial Office
    Daniel K. Nomura
    Bogumiła Zuga 32A Str.
    01-811 Warsaw, Poland
    T: +48 22 701 50 15

    Please log in or register to comment.